Morphic therapeutics market cap
WebApr 10, 2024 · Agile Therapeutics, Inc. PRINCETON, N.J., April 10, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of ... WebMar 3, 2024 · WALTHAM, Mass., March 02, 2024 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common …
Morphic therapeutics market cap
Did you know?
Web1 hour ago · In a report released today, Gregory Renza from RBC Capital reiterated a Buy rating on Nurix Therapeutics ( NRIX – Research Report ), with a price target of $30.00. The company’s shares opened ... WebMar 1, 2024 · WALTHAM, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral...
WebApr 9, 2024 · Also, the market prices HRMY at a forward multiple of 14.69. As a discount to earnings, Harmony ranks better than 79.66% of other biotech stocks to buy. Lastly, covering analysts peg HRMY as a ... WebJun 26, 2024 · WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 26, 2024-- Morphic Holding, Inc. (“ Morphic ”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per …
WebMar 6, 2024 · RBC Capital Markets Healthcare Conference Fireside Chat. May 18, 2024 at 1:55 PM EDT 41st Annual Cowen Health Care Conference. Mar 2, 2024 at 11:10 AM EST Morphic Financial and Operational Results 2024 Year End Conference Call. Mar 1, 2024 at 8: ... ©2024 Morphic Therapeutics, Inc. WebMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical ...
WebRevenue for Morphic Therapeutic (MORF) Revenue in 2024 (TTM): $70.8 M According to Morphic Therapeutic's latest financial reports the company's current revenue (TTM) is …
WebMorphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins … bodyslide game pathWebAccording to Morphic Therapeutic's latest financial reports the company's total assets are $0.36 B. A company’s total assets is the sum of all current and non-current assets, ... bodyslide fix clippingWebWALTHAM, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin … bodyslide for atomic beautyWeb1 day ago · Anika Therapeutics, Inc. as part of the agreement, the Company appointed Gary Fischetti as a Class III director. Fischetti will join two existing board members on a newly formed Capital Allocation Committee of the Board, which will make recommendations to the Board and support management's review of the Company's capital allocation. glibs newsWebAs of March 2024 Morphic Therapeutic's TTM earnings are -$63.4 M. companies: 7,317 total market cap: $83.626 T. Global ranking; Ranking by countries. America ... The … bodyslide how to resetWebApr 12, 2024 · Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, … glib of tongueWebMorphic Therapeutic (NASDAQ: MORF) develops oral integrin therapies for immunological, fibrotic, neoplastic and vascular diseases. Use the CB Insights Platform to explore Morphic Therapeutic's full profile. ... Market Cap 1.65B. Stock Price 41.82. About Morphic Therapeutic. glib plausible style of talk